PE20130775A1 - Antagonistas no competitivos de receptores nicotinicos - Google Patents
Antagonistas no competitivos de receptores nicotinicosInfo
- Publication number
- PE20130775A1 PE20130775A1 PE2012002210A PE2012002210A PE20130775A1 PE 20130775 A1 PE20130775 A1 PE 20130775A1 PE 2012002210 A PE2012002210 A PE 2012002210A PE 2012002210 A PE2012002210 A PE 2012002210A PE 20130775 A1 PE20130775 A1 PE 20130775A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- bicycle
- hydrochloride
- amine
- compounds
- Prior art date
Links
- 229960002715 nicotine Drugs 0.000 title abstract 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 230000036963 noncompetitive effect Effects 0.000 title abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 abstract 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A COMPUESTOS ANTAGONISTAS NO COMPETITIVOS DE RECEPTORES NICOTINICOS DE FORMULA (I) DONDE: R1 Y R2 INDIVIDUALMENTE ES H, ALQUILO DE C1-C6, ALQUILO C1-C6 SUSTITUIDO CON ARILO, ENTRE OTROS; R3 ES H, ALQUILO DE C1-C6, R7 ES INDIVIDUALMENTE H, ALQUILO DE C1-C6, O ALCOXI DE C1-C6; L1 ES UN CONECTOR SELECCIONADO DEL GRUPO FORMADO POR CR8R9, CR8R9CR10R11, O; R8,R9,R10,R11 ES H, ALQUILO C1-C6 , L2 ES UN CONECTOR SELECCIONADO DEL GRUPO FORMADO POR CH2, CH2CH2, CH2CH2CH2 Y CH2CH2CH2CH2. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE N,3-DIMETILESPIR[BICICLO[2.2.1]HEPTANO-2,1´-CICLOPROPAN]-3-AMINA; CLORHIDRATO DE N, 3-DIMETILESPIRO[BICICLO]OCT[5]ENO-2,1´-CICLOPENTAN]-3-AMINA Y CLORHIDRATO DE N,3-DIMETILESPIRO[BICICLO[2.2.2]OCTANO-2,1´-CICLOPENTAN]-3-AMINA, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN ELTRATAMIENTO O PREVENCION DE UNA ENFERMEDAD MEDIADA POR UN RECEPTOR NICOTINICO NEURONAL.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34902710P | 2010-05-27 | 2010-05-27 | |
| US37560610P | 2010-08-20 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130775A1 true PE20130775A1 (es) | 2013-07-21 |
Family
ID=44462072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002210A PE20130775A1 (es) | 2010-05-27 | 2011-05-24 | Antagonistas no competitivos de receptores nicotinicos |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US8809397B2 (es) |
| EP (1) | EP2576496B1 (es) |
| JP (2) | JP5893610B2 (es) |
| KR (1) | KR101856046B1 (es) |
| CN (2) | CN104557568B (es) |
| AU (1) | AU2011258553B2 (es) |
| BR (1) | BR112012030004A2 (es) |
| CA (1) | CA2799203C (es) |
| CL (1) | CL2012003274A1 (es) |
| CO (1) | CO6680603A2 (es) |
| ES (1) | ES2623373T3 (es) |
| IL (2) | IL223060A (es) |
| MX (1) | MX337106B (es) |
| NZ (1) | NZ603966A (es) |
| PE (1) | PE20130775A1 (es) |
| PH (1) | PH12012502300A1 (es) |
| PL (1) | PL2576496T3 (es) |
| RU (2) | RU2582339C2 (es) |
| SG (1) | SG185643A1 (es) |
| TW (1) | TW201200129A (es) |
| UY (1) | UY33409A (es) |
| WO (2) | WO2011149859A1 (es) |
| ZA (1) | ZA201208836B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG185643A1 (en) * | 2010-05-27 | 2012-12-28 | Targacept Inc | Nicotinic receptor non-competitive antagonists |
| SG11201401984VA (en) * | 2011-11-03 | 2014-05-29 | Targacept Inc | Nicotinic receptor non-competitive modulators |
| US8901177B2 (en) * | 2012-03-23 | 2014-12-02 | Targacept, Inc. | Method of treating bladder disorders |
| EP4267549A4 (en) * | 2020-12-23 | 2025-02-12 | The Broad Institute Inc. | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2931805A (en) * | 1958-11-10 | 1960-04-05 | Smith Kline French Lab | Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines] |
| US3290215A (en) * | 1963-10-29 | 1966-12-06 | Du Pont | Use of methanoindanamines as antiviral agents |
| US3317387A (en) * | 1964-05-25 | 1967-05-02 | Du Pont | Method of reducing the severity of influenza virus infections |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| JP2802486B2 (ja) | 1995-11-30 | 1998-09-24 | 花王株式会社 | トリシクロカルボン酸エステルおよびその製造法 |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| CN2284883Y (zh) | 1996-07-12 | 1998-06-24 | 陈智 | 纯滚活齿传动 |
| DE69733968T2 (de) | 1996-09-18 | 2006-06-01 | Applied Genetics Inc. Dermatics | Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| CA2393442A1 (en) | 1998-12-16 | 2000-06-22 | University Of South Florida | Exo-r-mecamylamine formulation and use in treatment |
| TW200306189A (en) * | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| WO2003087102A1 (en) * | 2002-04-18 | 2003-10-23 | Astrazeneca Ab | Furyl compounds |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7825147B2 (en) | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| WO2005060947A2 (en) * | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| MXPA06007026A (es) * | 2003-12-22 | 2006-08-31 | Astrazeneca Ab | Ligandos del receptor nicotinico de acetilcolina. |
| MX2007002045A (es) * | 2004-08-20 | 2007-03-29 | Targacept Inc | Uso de compuestos de n-arildiazaespiraciclicos en el tratamiento de adiccion. |
| AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| TW200845977A (en) * | 2007-03-30 | 2008-12-01 | Targacept Inc | Sub-type selective azabicycloalkane derivatives |
| WO2009039181A2 (en) * | 2007-09-17 | 2009-03-26 | State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Or. State Univ. | Sulfonamide-based organocatalysts and method for their use |
| AU2009221860A1 (en) * | 2008-03-05 | 2009-09-11 | Targacept, Inc. | Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes |
| SG185643A1 (en) * | 2010-05-27 | 2012-12-28 | Targacept Inc | Nicotinic receptor non-competitive antagonists |
| WO2013026852A2 (en) * | 2011-08-22 | 2013-02-28 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Derivatives of mecamylamine |
-
2011
- 2011-05-24 SG SG2012084828A patent/SG185643A1/en unknown
- 2011-05-24 US US13/699,757 patent/US8809397B2/en not_active Expired - Fee Related
- 2011-05-24 ES ES11724498.8T patent/ES2623373T3/es active Active
- 2011-05-24 JP JP2013512132A patent/JP5893610B2/ja not_active Expired - Fee Related
- 2011-05-24 BR BR112012030004A patent/BR112012030004A2/pt not_active IP Right Cessation
- 2011-05-24 RU RU2012157224/04A patent/RU2582339C2/ru not_active IP Right Cessation
- 2011-05-24 WO PCT/US2011/037630 patent/WO2011149859A1/en not_active Ceased
- 2011-05-24 KR KR1020127033480A patent/KR101856046B1/ko not_active Expired - Fee Related
- 2011-05-24 AU AU2011258553A patent/AU2011258553B2/en not_active Ceased
- 2011-05-24 CN CN201510013360.XA patent/CN104557568B/zh not_active Expired - Fee Related
- 2011-05-24 MX MX2012013618A patent/MX337106B/es active IP Right Grant
- 2011-05-24 CA CA2799203A patent/CA2799203C/en not_active Expired - Fee Related
- 2011-05-24 EP EP11724498.8A patent/EP2576496B1/en not_active Not-in-force
- 2011-05-24 PH PH1/2012/502300A patent/PH12012502300A1/en unknown
- 2011-05-24 PL PL11724498T patent/PL2576496T3/pl unknown
- 2011-05-24 WO PCT/US2011/037634 patent/WO2011149862A1/en not_active Ceased
- 2011-05-24 NZ NZ603966A patent/NZ603966A/en not_active IP Right Cessation
- 2011-05-24 PE PE2012002210A patent/PE20130775A1/es not_active Application Discontinuation
- 2011-05-24 CN CN201180026122.2A patent/CN102918021B/zh not_active Expired - Fee Related
- 2011-05-26 TW TW100118509A patent/TW201200129A/zh unknown
- 2011-05-26 UY UY0001033409A patent/UY33409A/es unknown
-
2012
- 2012-11-15 IL IL223060A patent/IL223060A/en active IP Right Grant
- 2012-11-22 ZA ZA2012/08836A patent/ZA201208836B/en unknown
- 2012-11-23 CL CL2012003274A patent/CL2012003274A1/es unknown
- 2012-12-21 CO CO12232450A patent/CO6680603A2/es active IP Right Grant
-
2014
- 2014-07-01 US US14/320,782 patent/US20140315877A1/en not_active Abandoned
-
2015
- 2015-08-27 US US14/837,023 patent/US9532974B2/en not_active Expired - Fee Related
- 2015-09-21 IL IL241743A patent/IL241743A0/en unknown
-
2016
- 2016-02-24 JP JP2016032562A patent/JP2016172717A/ja not_active Withdrawn
- 2016-03-28 RU RU2016111390A patent/RU2016111390A/ru not_active Application Discontinuation
- 2016-11-23 US US15/360,393 patent/US20170071878A1/en not_active Abandoned
-
2018
- 2018-01-23 US US15/877,725 patent/US10258582B2/en not_active Expired - Fee Related
-
2019
- 2019-04-15 US US16/383,880 patent/US10716770B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY161199A (en) | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 | |
| AR047992A1 (es) | Diaminopirimidinas como antagonistas de p2x3 y p2x2/3 | |
| MX2012004848A (es) | Compuestos heterociclicos triciclicos. | |
| CY1117792T1 (el) | Ανταγωνιστες toy trpv4 | |
| CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
| AR080688A1 (es) | Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina | |
| UA110259C2 (uk) | Похідні піролопіримідину і пурину | |
| AR083831A1 (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
| ECSP11011189A (es) | Moduladores de los receptores tipo toll | |
| UY31638A1 (es) | Furo[3,2-c]piridina y tieno[3,2-c]piridinas | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EA200970928A1 (ru) | Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения | |
| HRP20130614T1 (en) | Novel pyrazole-substituted arylamides | |
| PE20081837A1 (es) | Derivados de quinuclinidol como antagonistas de los receptores muscarinicos | |
| PE20121066A1 (es) | Derivados de diazahomoadamantano y metodos para usarlos | |
| AR059905A1 (es) | Pirrolidina-3-ilaminas n-substituidas como antagonistas del receptor histamina-3, composicion farmaceutica y proceso para preparar el compuesto | |
| ATE473221T1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus | |
| EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| CY1117261T1 (el) | [4-(5-αμινομεθυλο-2-φθορο-φαινυλο)-πιπεριδιν-1-υλο]-[7-φθορο-1-(2-μεθοξυ-αιθυλο)-4τριφθορο μεθοξυ-1η-ινδολ-3-υλο]-μεθανονη ως αναστολεας τρυπτασης maστοκυτταρων | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
| PE20060176A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| PE20130775A1 (es) | Antagonistas no competitivos de receptores nicotinicos | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
| AR039651A1 (es) | Derivados de isoquinolina | |
| CY1117826T1 (el) | Ενωσεις μορφiνανης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |